[wpaudio url=”/blog/media/podcasts/Andersen_Peter_finished.mp3″ text=”Click here to play the Peter Anderson Podcast” dl=”0″]
Summary: Dr. Peter Andersen is Vice President of Vaccine Research and Development at Statens Serum Institut (SSI). The WGND had the opportunity to talk with Dr. Andersen on a recent article entitled “A multistage tuberculosis vaccine that confers efficient protection before and after exposure” that we covered in a previous TB R&D Weekly Update. The article is published in Nature Medicine in February 2011. In the interview, Dr. Andersen provides an overview of his present research and the article, possible integration of a vaccine that protects pre- and post- exposure into TB treatment, and the challenges for TB vaccine development.
Additional TB R&D News:
New findings on drug tolerance in TB suggest ideas for shorter cures
BC Scientists Pioneer Method to Trace TB Outbreak
Traditional drug-discovery model ripe for reform
Sterilizing Activity of Second-Line Regimens Containing TMC207 in a Murine Model of Tuberculosis